Skip Universal NavigationSkip to Main Content
GE Annual Report 2001
GE.com Home Investor Relations Press Room Contact Us
People, Performance, Possibilities
GE.com Home
Annual Report Home
Financial Highlights
Letter to Share Owners
GE Values
People, Performance, Possibilities
More than a Century of Innovation
GE at a Glance
GE Businesses
Board of Directors
Management
Financial Section
Corporate Information
Proxy Statement
Printable Version
Feedback
Greg Lucier
Hiroyuki Mitani
Caroline Reda
Emmett Harrigan, Chip Hills, Levent Neymen, Matt Santomenna
Danielle Walker, Marshall Jones
Beth Klein, Tom Hook
Claudi Santiago
Charlene Begley
Dennis Bianchi
Colleen Athans
Paul Bossidy
Chih Chen
Jim Shepard, Maryrose Sylvester
Mary McNamara
Taketo Yamakawa
Enrique Lechuga
Lynn Pendergrass, Michael A. Jones
Jason Smith
Rachel Hands
Bill Smith
Tony Hashem
Keith Moye
Dr. Beatriz Vidales
Bori Sari
Catherine Ayreau
Michelle Seward
Letter to Share Owners - Introduction
Beth Klein President and CEO, GE Medical Systems, Americas; Tom Hook General Manager, GE Medical Systems, Global PET

Beth: Cancer killed more than six million people last year. Our customers said, "Help us. Build a better tool for detecting cancer – give us more speed and precision – so we can diagnose it earlier and treat it more effectively."

Tom: We integrated two technologies – "multi-slice" CT (computed tomography), which performs anatomical imaging, and PET, which provides functional imaging – into one system, the Discovery™ LS.

Beth: A traditional cancer diagnosis can take four to six weeks. Discovery LS accomplishes most of the process in one 30-minute procedure, with greater clinician confidence and patient comfort.

Tom: Even though Discovery LS has more lines of computer code than the first mission to the moon, we launched more than 12 months ahead of schedule.  We used a concurrent engineering strategy and a truly global team to design and manufacture core components simultaneously in Wisconsin, China and Israel.

Beth: Eventually this technology will be used by oncologists, neurologists and cardiologists to diagnose and treat a full range of diseases.

Tom: Discovery LS is also GE's platform for molecular imaging and genomics, which will define the future of healthcare.

Beth: And give us new opportunities to make a difference in people's lives.

GE Annual Reports | Previous Stock Close | Electronic Delivery Privacy Policy | Terms & Conditions
©General Electric Company 2002